# C. Klingler\*, L.-M. Scheide\*, M. Goisauf+, M. Hummel\*, C. Specht\* Stakeholder Management: Perspectives of donors on biobank cooperation with industry

### BACKGROUND

For the purpose of successful stakeholder management in the biobank sector, an understanding of expectations of the various stakeholders is fundamental. Social science methods such as the focus group offer the following appropriate approach:

"Your primary aim is to try to understand a new area, or investigate people's attitudes, opinions and beliefs, and you will not be able to know what the range of answers will be. You need to avoid forcing people into answering questions in particular ways, for you cannot predict how they will want to answer a particular question."

(Dawson et al., 1993)

Patient representatives in particular offer valuable expert knowledge. Furthermore they bring along both experience in communication with potential donors and other stakeholders, such as industry representatives and researchers.

### **RESEARCH QUESTION**

How is cooperation between academic biobanks and industrial partners viewed by patient representatives and patients in the light of their potential role as donors?

### **RESULTS 2: PATIENT REPRESENTATIVES ON INDUSTRIAL COOPERATION – THEMES DISCUSSED**

- 1. Discussion about a Win-win-but-no-business-model
- Industry cooperation requires a "careful weighing of different options for action"
- It is a matter of "ethical" and "sensitive matters"
- "interests of each partner" should be taken into account
- Evaluation of non-university research should "always be about quality" and Responsibility
- 2. Discussion about anonymisation and various clinical data
- There is a need for talking about different types of data and their meanings for patients
- "Data sovereignty must lie with the patient"
- 3. Discussion about the need to convince donors and a well thought-out consent form
- Explanation should be "as transparent, as clear and as far-reaching" as possible • Formulation in "simple language"
- 4. Discussion about paying in knowledge
- Transfer of knowledge is important for donors
- Biobanks should receive the results of research
- Necessity of simplification of research results for former donors

### 5. Discussion about a clearing house with equal representation • Establishment of a control body in a biobank law

important stakeholders

### 6. Discussion on legal advice and uniform guidelines

- Prevention of violation
- Creation of "uniform guidelines", "conditions for payment of money" and other contractual regulation, up to a "biobank law"

### **DATA COLLECTION**

- Focus group with eight patient representatives to open up the perspective of potential donors
- Facalitator and a co-facalitator
- Interview guide for orientation purposes
- Important points were fixed on moderation cards

### DATA ANALYSIS

Schreier's steps of **Qualitative Content** Analysis (QCA)

- **1. Deciding** on the research question
- 2. Selecting the material
- **3. Building a coding frame** from the material by creating categories
- 4. **Dividing** the material into units of coding
- 5.+6.+7. Trying out, evaluating and modifying the coding frame and main analysis
- 8. Presenting a systematic and materialreducing description of the patient representatives points of view using the coding frame

# **RESULTS 1: PATIENT REPRESENTATIVES ON INDUSTRIAL COOPERATION – OVERVIEW**

### **Emic Perspective**

Presumed impact of industry cooperation

Hope for purposeful research in the expectation of the patient vs. fear of abuse

Ideal of cooperation between all experts for the benefit of patients

Situation of acceptance of industry cooperation

Acceptance of industry cooperation if it is well thought out

Diversity with regard to patients' opinions on industry cooperation

Need for information and a belief in knowledge on the side of a potential donor.


(Vgl. Schreier 2012)


• Explicit talking about data involves negotiating "clear rules" and is again related to educating donors about the possible loss of "rights" to their own data

• Demand for a joint "process" for drawing up a well thought-out consent document, especially with help of patient representatives

• Maybe there is a lack of interest in recovery on the part of industry, but research results should "not be made a trade secret"

• E.g. an independent ethics committee, a commission based on the example of an auditing association at banks and a commission consisting of all





## OUTLOOK

Academic biobanks should expand cooperation with industry, and the German Biobank Node (GBN) will develop best practice examples eligible for all involved stakeholders. Therefore, these results from the focus group of patient representatives are important for GBN to prepare a successful dialogue between the biobanks and different stakeholder groups. Beside the patient representatives we have conducted qualitative interviews with representatives from pharmaceutical companies. The detailed analysis is expected at the end of 2020 and will provide the second data base for this dialogue. The third group are the biobanks themselves. One workshop has been conducted with biobank partners of the German Biobank Alliance and resulted in a position paper on collaboration with industry (Baber et al.). A workshop is planned for summer 2021 taking the results mentioned above into account and inviting all relevant experts being involved in processes around industry cooperation.

### LITERATURE

### Contact

\* Central Office German Biobank Node Charité – Universitätsmedizin Berlin Campus Virchow Klinikum (CVK) Augustenburger Platz 1, D-13353 Berlin

National Coordinator Prof. Michael Hummel michael.hummel@charite.de **Executive Director** Dr. Cornelia Specht cornelia.specht@charite.de

+ Biobanking and Biomolecular Resources Research Infrastructure – European Research Infrastructure Consortium (BBMRI-ERIC)

# German **Biobank Node** bbmri.de

Dawson S, Manderson L, Tallo V L. A Manual for the Use of Focus Groups. INFDC. 1993. **Schreier M.** Qualitative Content Analysis in Practice. Sage.

Baber R, Hummel M, Jahns R, von Jagwitz-Biegnitz M, Kirsten R, Klingler C, Nussbeck SY, Specht C. Position Statement from the German Biobank Alliance on the Cooperation Between Academic Biobanks and Industry Partners. In: Biopreservation and Biobanking. 2019. Vol.17, No.4.



@bbmri\_de

SPONSORED BY THE




Federal Ministry and Research



mind. of Piece Service. Quality.



Sustair Topic 11 Cornelia



Specht